Core Biomedicine Raises $21M Series A to Advance Precision Oncology Pipeline

▤ Summary

Core Biomedicine raised $21 million in Series A financing to move its precision oncology pipeline into early clinical development. The round was co-led by UTokyo Innovation Platform and Elikon Venture, with additional support from a Japanese government program. The company uses a lineage-based approach that focuses on biological pathways shared across tumors rather than only genetic mutations. Core Biomedicine says this strategy could expand the addressable market for future cancer therapies and improve target discovery.

$ Funding

▦ Linked Companies